MediciNova (MNOV) Competitors $1.32 +0.00 (+0.20%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNOV vs. IMMP, TKNO, SCPH, ALLO, SGMT, SOPH, AARD, FENC, TLSA, and GALTShould you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include Prima BioMed (IMMP), Alpha Teknova (TKNO), scPharmaceuticals (SCPH), Allogene Therapeutics (ALLO), Sagimet Biosciences (SGMT), SOPHiA GENETICS (SOPH), Aardvark Therapeutics (AARD), Adherex Technologies (FENC), Tiziana Life Sciences (TLSA), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. MediciNova vs. Its Competitors Prima BioMed Alpha Teknova scPharmaceuticals Allogene Therapeutics Sagimet Biosciences SOPHiA GENETICS Aardvark Therapeutics Adherex Technologies Tiziana Life Sciences Galectin Therapeutics MediciNova (NASDAQ:MNOV) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership. Which has better earnings & valuation, MNOV or IMMP? MediciNova has higher earnings, but lower revenue than Prima BioMed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediciNova$1MN/A-$11.04M-$0.25-5.28Prima BioMed$5.14M48.55-$28.01MN/AN/A Is MNOV or IMMP more profitable? Prima BioMed's return on equity of 0.00% beat MediciNova's return on equity.Company Net Margins Return on Equity Return on Assets MediciNovaN/A -23.12% -21.85% Prima BioMed N/A N/A N/A Which has more risk and volatility, MNOV or IMMP? MediciNova has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Prima BioMed has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Do analysts rate MNOV or IMMP? MediciNova presently has a consensus price target of $7.00, suggesting a potential upside of 430.30%. Prima BioMed has a consensus price target of $7.00, suggesting a potential upside of 311.76%. Given MediciNova's stronger consensus rating and higher possible upside, research analysts plainly believe MediciNova is more favorable than Prima BioMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer MNOV or IMMP? In the previous week, MediciNova had 1 more articles in the media than Prima BioMed. MarketBeat recorded 1 mentions for MediciNova and 0 mentions for Prima BioMed. MediciNova's average media sentiment score of 0.97 beat Prima BioMed's score of 0.00 indicating that MediciNova is being referred to more favorably in the media. Company Overall Sentiment MediciNova Positive Prima BioMed Neutral Do institutionals and insiders hold more shares of MNOV or IMMP? 9.9% of MediciNova shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 13.6% of MediciNova shares are owned by company insiders. Comparatively, 3.1% of Prima BioMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryMediciNova beats Prima BioMed on 8 of the 12 factors compared between the two stocks. Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNOV vs. The Competition Export to ExcelMetricMediciNovaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.37M$3.06B$5.76B$9.72BDividend YieldN/A2.24%4.40%4.10%P/E RatioN/A20.9030.1925.84Price / SalesN/A390.30474.98187.82Price / CashN/A43.2325.7828.79Price / Book1.239.649.425.99Net Income-$11.04M-$54.08M$3.27B$265.29M7 Day Performance0.76%2.62%2.05%2.53%1 Month Performance-9.59%4.05%3.58%0.92%1 Year Performance8.20%9.48%30.09%18.70% MediciNova Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNOVMediciNova2.2669 of 5 stars$1.32+0.6%$7.00+430.3%+7.6%$64.37M$1M0.0010Gap UpIMMPPrima BioMed0.9692 of 5 stars$1.78+2.9%$7.00+293.3%-27.2%$253.94M$5.14M0.002,021Positive NewsUpcoming EarningsTKNOAlpha Teknova1.6439 of 5 stars$4.41-6.0%$10.00+126.8%-4.8%$250.99M$37.74M-10.50240SCPHscPharmaceuticals4.5245 of 5 stars$4.78+3.9%$14.00+192.9%-9.7%$245.17M$36.33M-2.6430News CoveragePositive NewsAnalyst ForecastGap UpTrading HaltedALLOAllogene Therapeutics2.6094 of 5 stars$1.09-0.9%$8.44+674.7%-54.4%$244.07M$20K-0.98310SGMTSagimet Biosciences2.8131 of 5 stars$7.55-1.6%$25.67+240.0%+141.8%$235.28M$2M-4.138SOPHSOPHiA GENETICS2.915 of 5 stars$3.49+0.6%$8.00+129.2%-3.5%$234.50M$65.17M-7.93520Positive NewsAARDAardvark TherapeuticsN/A$10.44-3.2%$32.80+214.2%N/A$233.89MN/A0.0018Gap DownFENCAdherex Technologies1.9173 of 5 stars$8.20-1.9%$13.33+62.6%+51.9%$232.52M$47.54M-19.5210News CoverageAnalyst RevisionTLSATiziana Life Sciences0.5459 of 5 stars$1.89-4.1%N/A+68.9%$230.19MN/A0.008GALTGalectin Therapeutics2.3789 of 5 stars$3.90+9.2%$6.00+53.8%+77.5%$228.70MN/A-6.099 Related Companies and Tools Related Companies IMMP Competitors TKNO Competitors SCPH Competitors ALLO Competitors SGMT Competitors SOPH Competitors AARD Competitors FENC Competitors TLSA Competitors GALT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNOV) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access